Keyphrases
ABCC2
10%
ABCG2
10%
Adjuvant Combination
10%
Adverse Effects
10%
After Surgery
20%
ARHGEF10
10%
ATP Binding Cassette Subfamily B Member 1 (ABCB1)
10%
Breast Cancer
100%
Breast Cancer Treatment
10%
Cause-specific
10%
Combination Chemotherapy
10%
Competing Events
10%
Confidence Interval
20%
Cox Regression Model
10%
Cumulative Incidence
20%
Cyclophosphamide
10%
CYP1B1
10%
CYP3A5
40%
Cytochrome P450 1A1 (CYP1A1)
10%
Cytochrome P450 3A (CYP3A)
10%
Cytochrome P450 3A4 (CYP3A4)
10%
Danish Registry
10%
Delayed-return
10%
Distant Metastasis
10%
Docetaxel
10%
EphA4
10%
EPHA5
10%
EPHA6
10%
ERCC1
10%
ERCC2
10%
FGD4
10%
Genotype
10%
GSTP1
10%
Hazard Ratio
20%
Heterozygote
10%
Homozygote
40%
Labour Market Attachment
30%
Metastatic Breast Cancer
10%
Postmenopausal Women
30%
Return to Work
100%
Single nucleotide Polymorphism
100%
SLCO1B1
10%
SLCO1B3
10%
TaqMan Assay
10%
Taxane-based Chemotherapy
100%
Transient Receptor Potential Vanilloid 1 (TRPV1)
10%
Treatment Toxicity
10%
Women with Breast Cancer
10%
Medicine and Dentistry
Adverse Event
16%
Breast Cancer
100%
Breast Cancer Resistance Protein
16%
Cancer Therapy
16%
Combination Chemotherapy
16%
Cumulative Incidence
33%
Cyclophosphamide
16%
CYP1B1
16%
CYP3A
16%
CYP3A4
16%
Cytochrome P450 1A1
16%
Cytochrome P450 3A5
66%
Docetaxel
16%
Hazard Ratio
33%
Homozygote
66%
Metastatic Breast Cancer
16%
Premenopause
50%
Proportional Hazards Model
16%
Single Nucleotide Polymorphism
100%
TRPV1
16%
Nursing and Health Professions
Adverse Event
25%
Breast Cancer
100%
Breast Cancer Resistance Protein
25%
Cancer Therapy
25%
Combination Chemotherapy
25%
Confidence Interval
50%
Cyclophosphamide
25%
CYP1B1
25%
CYP3A
25%
CYP3A4
25%
Cytochrome P450 1A1
25%
Cytochrome P450 3A5
100%
Docetaxel
25%
Hazard Ratio
50%
Metastatic Breast Cancer
25%
Proportional Hazards Model
25%
Psychology
Breast Cancer
100%
Hazard Ratio
20%
Proportional Hazards Regression Model
10%
Regression Model
10%
Return to Work
100%
Social Sciences
Danish
33%
Labor Market
100%
Economics, Econometrics and Finance